153 related articles for article (PubMed ID: 36809598)
1. Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.
Rosenbach K; Park M; Sanchirico M; Nwose O; Paris K
J Clin Immunol; 2023 Jul; 43(5):912-920. PubMed ID: 36809598
[TBL] [Abstract][Full Text] [Related]
2. Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.
Fasshauer M; Borte M; Bitzenhofer M; Pausch C; Pittrow D; Park M; Gladiator A; Jandus P
Adv Ther; 2023 Dec; 40(12):5168-5187. PubMed ID: 37751025
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies - real-world data from the IG TATRY study.
Heropolitańska-Pliszka E; Pac M; Pietrucha B; Machura E; Pukas-Bochenek A; Chrobak E; Bień E; Malanowska M; Pituch-Noworolska A; Drygała S; Kamieniak M; Kasprzak J; Mach-Tomalska M
Expert Rev Clin Immunol; 2023; 19(10):1281-1291. PubMed ID: 37489744
[TBL] [Abstract][Full Text] [Related]
4. Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants.
Meckley LM; Wu Y; Tzivelekis S; Gandhi V; Gladiator A
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):568-574.e1. PubMed ID: 34224864
[TBL] [Abstract][Full Text] [Related]
5. Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.
Keith PK; Cowan J; Kanani A; Kim H; Lacuesta G; Lee JK; Chen J; Park M; Gladiator A
Allergy Asthma Clin Immunol; 2022 Aug; 18(1):70. PubMed ID: 35934726
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies.
Paris K; Haddad E; Borte M; Brodszki N; Dérfalvi B; Maródi L; Hussain I; Darter A; Engl W; Leibl H; McCoy B; Yel L
Immunotherapy; 2019 Apr; 11(5):397-406. PubMed ID: 30626238
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
Shapiro RS
Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents.
Suez D; Kriván G; Jolles S; Stein M; Gupta S; Paris K; van Hagen PM; Brodszki N; Engl W; Leibl H; McCoy B; Yel L
Immunotherapy; 2019 Aug; 11(12):1057-1065. PubMed ID: 31268374
[No Abstract] [Full Text] [Related]
10. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.
Gupta S; Stein M; Hussain I; Paris K; Engl W; McCoy B; Rabbat CJ; Yel L
Ann Allergy Asthma Immunol; 2019 Sep; 123(3):271-279.e1. PubMed ID: 31228628
[TBL] [Abstract][Full Text] [Related]
14. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
[No Abstract] [Full Text] [Related]
15. Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.
Meckley LM; Wu Y; Ito D; Berner T; McCoy B; Yel L
BMC Immunol; 2020 May; 21(1):24. PubMed ID: 32366233
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies.
Patel NC; Torgerson T; Thakar MS; Younger MEM; Sriaroon P; Pozos TC; Buckley RH; Morris D; Vilkama D; Heimall J
J Clin Immunol; 2023 Oct; 43(7):1557-1565. PubMed ID: 37266769
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.
Gupta S; DeAngelo J; Melamed I; Walter JE; Kobayashi AL; Bridges T; Sublett JW; Bernstein JA; Koterba A; Manning M; Maltese J; Hoeller S; Turpel-Kantor E; Kreuwel H; Kobayashi RH
J Clin Immunol; 2023 Aug; 43(6):1414-1425. PubMed ID: 37160610
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis.
Shapiro R
J Clin Immunol; 2010 Mar; 30(2):301-7. PubMed ID: 20082124
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
[TBL] [Abstract][Full Text] [Related]
20. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
[No Abstract] [Full Text] [Related]
[Next] [New Search]